Following promising trial results, retatrutide, a new peptide therapy for managing type 2 metabolic disorder, has received conditional approval from Great Britain's Healthcare and Regulatory Agency ( https://poppyiaoj093758.blogs-service.com/72065189/retatrutide-compound-peptide-british-approval-and-access